University of Pennsylvania

ScholarlyCommons
Statistics Papers

Wharton Faculty Research

1995

Optimal Confidence Sets, Bioequivalence, and the Limaçon of
Pascal
Lawrence D. Brown
University of Pennsylvania

George Casella
J. T. Gene Hwang

Follow this and additional works at: https://repository.upenn.edu/statistics_papers
Part of the Statistics and Probability Commons

Recommended Citation
Brown, L. D., Casella, G., & Hwang, J. (1995). Optimal Confidence Sets, Bioequivalence, and the Limaçon
of Pascal. Journal of the American Statistical Association, 90 (431), 880-889. http://dx.doi.org/10.1080/
01621459.1995.10476587

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/statistics_papers/492
For more information, please contact repository@pobox.upenn.edu.

Optimal Confidence Sets, Bioequivalence, and the Limaçon of Pascal
Abstract
We begin with a decision-theoretic investigation into confidence sets that minimize expected volume at a
given parameter value. Such sets are constructed by inverting a family of uniformly most powerful tests,
and hence they also enjoy the optimality property of being uniformly most accurate. In addition, these
sets possess Bayesian optimal volume properties and represent the first case (to our knowledge) of a
frequentist 1 – α confidence set that possesses a Bayesian optimality property. The hypothesis testing
problem that generates these sets is similar to that encountered in bioequivalence testing. Our sets are
optimal for testing bioequivalence in certain settings; in the case of the normal distribution, the optimal
set is a curve known as the limaçon of Pascal. We illustrate the use of these curves with a
biopharmaceutical example.

Keywords
Bayes estimation, decision theory, frequentist estimation, hypothesis testing, uniformly most accurate,
uniformly most powerful

Disciplines
Statistics and Probability

This journal article is available at ScholarlyCommons: https://repository.upenn.edu/statistics_papers/492

Optimal Confidence Sets, Bioequivalenc:e, and the Lim~n of Pascal
Lawrence D. Brown1
George Casella2 ·

J. T. Gene Hwang1
Cornell University, Ithaca, N.Y. 14853

. BU-1205-M

April1993

Key words and phrases: decision theory, Bayes estimation, frequentist estimation, hypothesis testing,
uniformly most powerful, uniformly most accurate

AMS 1990 Subject Classification: Primary 62F25, 62C99; Secondary: 62F03
1

Research supported by National Science Foundation Grant No. DMS9107842.

2

Research supported by National Science Foundation Grant No. DMS9100839 and National Security
Agency Grant No. 90F-073.

-1-

Abstract
We begin with a decision-theoretic investigation into confidence sets that minimize expected
volume at a given parameter value. Such sets are constructed by inverting a family of uniformly
most powerful tests, hence also enjoy the optimality property of being uniformly most accurate. In
addition, these sets possess Bayesian optimal volume properties, and represent the first case (to our
knowledge) of a frequentist 1-a confidence set that possesses a Bayesian optimality property.
The hypothesis testing problem that generates these sets is similar to that encountered in
bioequivalence testing. Our sets are optimal for testing bioequivalence in certain settings, and in the
case of the normal distribution, the optimal sets are curves known as the
illustrate the use of these curves with an example.

lim~on

of Pascal. We
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1. Introduction

The construction of good set estimates of a parameter, both frequentist and Bayesian, has long
been a goal of statisticians. The formalization of "good" set estimates is usually in terms of some
measure of the size of the set, often taken to be the volume of the set. Alternatively, the size of the
set can be measured by its probability of false coverage.

Thus, if C(x) is a set estimate of a

parameter 8, P 8 (8 E C(X)) is the probability of true coverage, while P 8(8' E C(X)), 8 =f. 8', is the
probability of false coverage.
The false coverage of C(x) can be related to its volume through the Ghosh-Pratt identity
(Ghosh 1961; Pratt 1961),
(1.1)
but this has rarely been used in establishing volume optimality. An exception is the work of Cohen
and Strawderman (1973).
Equation (1.1) illustrates that possession of an optimal expected volume is a somewhat stronger
property than possessing optimal false coverage probabilities, since expected volume can be regarded
as a sum over all false coverages.

Since admissibility with respect to expected volume implies

admissibility with respect to false coverage probability, a procedure with optimal expected volume
will have attractive false coverage properties. However, the converse is not true. As domination of
false coverage probabilities ties directly into testing theory, where much is known about optimality,
we find many cases where set estimates with optimal false coverage properties do not have optimal
volume properties.

For example, the usual multivariate normal confidence set cannot be uniformly

dominated in false coverage, but it can be dominated in volume (see Casella and Hwang 1983 or
Shinozaki (1989).
There is, however, an instance in which false coverage and volume are equivalent. That is when
there is interest in producing a procedure that is optimal at some point in the parameter space.
Thus, if there is interest in minimizing volume at a parameter value 8=8*, then this can be
accomplished by minimizing all of the false coverages at 8=8*. Doing so brings the construction of
optimal volume confidence sets back into a Neyman-Pearson testing set-up.
At first it may seem surprising that one can construct a confidence set that has optimal size at

8=8* while maintaining a nominal coverage probability for all parameter values.

However, this

problem is a version of what was solved by Sterne (1954) in the binomial case (see also Crow 1956).
For X"" binomial (n, p), Sterne proposed to construct a confidence set for p by inverting acceptance
regions composed of the fewest X values necessary to have a rejection region with prespecified size a.
He noted that such a set minimized the sum of the n+ 1 lengths.

It turns out that such a

construction, which is a Neyman-Pearson-type construction, will yield sets of minimum volume at

0=0*.
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Interestingly, there is another aspect to the construction outlined here.

We will see that the

process of minimizing the expected volume at a value 0=0* can also be used to minimize a Bayesian
expected volume, that is, an expected volume integrated over a prior distribution.

Thus, our

construction gives a frequentist confidence set (one that maintains a nominal coverage probability)
that optimizes a Bayesian measure of volume.
In Section 2 we formalize the decision-theoretic problem, and establish an optimality theorem in
the frequentist setting.

We also consider the normal case in detail, where the

lim~on

of Pascal

appears. Section 3 connects these results to the Bayesian formulation, and shows how to construct
optimal frequentist/Bayes intervals. Section 4 addresses the unknown variance case, and we see that
the known variance optimality results can be generalized to this case. Lastly, Section 5 discusses the
connections to the problem of bioequivalence testing.
bioequivalence confidence sets based on the

lim~on

We also present an example showing how

can provide sharper inferences.
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2. The Frequentist Interpretation
2.1 A General Formulation
Let X have continuous density (for convenience) f( ·10) with respect to Lebesque measure. Given
that we observe X = x, we set up a confidence set for 0. This set, C{x), may be a randomized set,
and has inclusion probability

(2.1)
That is, cp(O lx) is the probability of including the value 0 in the set when x is observed.

For

nonrandomized sets cp(O lx) = 1(0 E C(x)), the indicator function of the set C{x). {Randomized rules
are only included for completeness of the theory, as they should never be recommended in practical
applications.)
The volume of the set C{x), vol ( C{x)), with respect to Lebesque measure, is given by
vol(C(x)) = J cp(t lx)dt,

e

(2.2)

.

with expected volume
E0vol(c(x)) = J vol(C(x))f(xiO)dx.

(2.3)

$

In addition to calculating (2.3) as a measure of size, it i.s usual to calculate the frequentist coverage
probability of the set C(x), that is
P 0 (oec(x))= Jcp(Oix)f(xiO)dx.

(2.4)

$

A standard frequentist requirement is to have this coverage probability greater than some
nominal level, say 1-a, for all values of 0.

Subject to that constraint, we seek to minimize the

expected volume of C(x) at a selected value of 0. Without loss of generality we take 0=0 and, to
avoid trivial pathologies, 0 < a < 1. Thus, the problem of interest becomes:
Over all confidence sets C(x), minimize E0 vol(C(X)) subject to
P0

(o E C(X))~ 1-a for all 0.

(2.5)

Before stating and proving a formal theorem, note that the specifying of 0=0 in the volume
requirement, which puts a particular importance on this value, makes one think of a hypothesis
testing formulation. However, the formulation of a hypothesis test that is equivalent to (2.5) is not
entirely straightforward, for the specified value 0=0 is not part of the null hypothesis, but of the
alternative hypothesis.
Consider testing

(2.6)
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where X - f( ·I 0).

The most powerful (Neyman-Pearson) size a test is given by a rejection rule

satisfying

1/Jno
u =

{

1
0

iff(xiO)>k(00)f(xi00)
otherwise

for which E00 (.,p 00(X)) =a. As in (2.1), define confidence sets C* with
~*( 0 Ix)

= 1 - .,p0(x) .

(2.7)

It is this confidence set that solves the problem in (2.5). Note that in the usual non-randomized case
the confidence set is
C*(x) = { 0 : f(x I0) > f(x I 0) / k(O)}.
Theorem 2.1:

Let X -f( ·10), and let ~*(Oix) be given by (2.7).

minimizes the expected volume at 0
Proof:

{2.8)
The confidence set C*(x)

= 0 among all1-a confidence sets.

The proof is based on the Ghosh-Pratt identity (Ghosh 1961; Pratt 1961), and can be found

in Pratt's paper (along with the one-dimensional normal example). We have for any confidence set
C(x)
E 0vol(c(x)) =

J vol(c*(x))f(xiO)dx = JJso(Oix)dO f(xiO)dx,
$

$8

where <p((J Ix) is the probability that () is included in C(x) when x is observed. Interchanging the
order of integration gives
E 0vol(c(x)) =

JJ so(Oix)f(xiO)dxdO = JP 0 (o e C(X))do.
eg;

(2.9)

e

The integrand in (2.9) is the probability of false coverage, which is minimized, subject to (2.5), by the
uniformly most accurate set C*(x), and in turn produces the minimum expected volume.

0

It should be noted that any weighted volume measure can be used and Theorem 2.1 would

remain valid. That is, if we measure the size of a set C(x) by

E0 size(c(x)) =

J
g;

[Je

<p(Oix)v(O)dO]dx,

(2.10)

where v( ·) > 0 is some weight function, then C*(x) of (2.8) minimizes (2.10) over all 1-a confidence
sets.
2.2 The Normal Case
To better understand the behavior of C*(x), we look at it more closely in the normal case. If X
has a p-variate normal distribution, X"' Np(O, I), then for the hypothesis test (2.6) we would reject
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where k*(00 ) is chosen to give the test size a. Thus, the confidence set is C*(x) = {0 : x'O ~ k*(O)}.
To evaluate the form of k*(O), we use the fact that W = O'X/1 0 I""' n(l (}I, 1), regardless of the
dimension of X. Then, for (} =P 0 the coverage probability is
P0

(o E c*(x)) = P0(x'o ~ k*(o))
=

P(IOIW~k*(o))

= <I>(a)
for k*(O) = I(} I (lOl-a), where <I>(·) is the standard normal cdf. Choosing a= <I>-1(1-a) yields a 1a confidence interval.

To better understand the shape of C*(x), write x'O = Ix 1101 cos /3, where cos f3 = x'O /I x 1101,
and f3 is the angle between x and 0. Then, in the normal case the optimal confidence set is
C*(x) =

{0:

(2.10)

101 :5a+ lxlcos/3}.

The boundary of this set is the main lobe of a curve known as the

lim~on

that is often used in calculus courses to illustrate polar coordinate techniques.

of Pascal, a curve
(The

lim~on

was

actually studied by Etienne Pascal, the father of the famous Blaise Pascal, see Archibald 1900). The
lim~n

is shown in Figure 1, and the confidence set (2.10) is graphed in Figure 3 for various values

of x when p = 2. It is interesting to note that when x = 0 the set is a sphere, but as x moves away
from zero there is a distinct nonconvexity to the set. (The

lim~on

is actually a generalization of the

cardiod, a "heart-shaped" polar curve.) As x tends toward infinity the
sphere.
lim~on

In higher dimensions, the

shape is retained.

becomes more like a

If we graph a higher dimensional

by identifying the x-axis with the data x, and using f3 as the angle between 0 and x, equation

(2.10) will resemble the
the

lim~on

lim~on

lim~on

lim~on

in Figure 1. The remainder of the set is then generated by rotating

about the x-axis.

Notice that C*(x) has coverage probability <J>(a) regardless of the dimension of the problem. In
one

dimension

some

further

simplifications

can

be

made.

Here

we

have

W

I X Isgn( OX) "" n( I0 I, 1), and
C*(x) = {8 : IxI sgn(Ox) ~lOl-a}= {0 : min(O, x-a) :5 () :5 max (0, x +a)} .

(2.11)

The 95% confidence interval has a = 1.645, and is equal to x ± 1.645 for small IxI· The usual twosided 95% confidence interval is x ± 1.96. Thus, C*(x) is narrower than the usual interval for small
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values of x, but wider for larger values. C*(x) does have an interesting property, however, in that it
falls on one side of zero for smaller values of IxI than the usual interval, thus allowing an
experimenter more power in making formal conclusions about the sign of 0. Figure 2 compares C*(x)
with the usual one-dimensional interval.
As mentioned before, the one-dimensional C*(x) was first derived by Pratt (1961), who also
discussed the connection with the Sterne-Crow intervals for a binomial success probability {Crow
1956). However, the interval (2.11) has another history, emerging from the work of Hsu {1981, 1984).
He derived the interval in the context of a multiple decision problem, where one is interested in
confidence intervals for the distance from the best mean. A discussion of C*(x), and demonstration of
some properties, can be found in Exercise 9.31 of Casella and Berger, 1990.

=

The expected volume, at 0

0, can also be evaluated for C*(x).

Since C*(x) =

{0: 10 I :5 w+a}, where W "'n( 10 I, 1), we have

F;,vol(C*(X)) ~

=

![!

1(0 E C*(x))f(x IO)dx] dO

I[

{x: j;

e
=

I

0

I

1

{2.12)
f(xiO)dx] dO

~lOl-a}

4>(a-1 0 I) dO ,

e

where the last equality follows from the fact that for X"' N(O, 1), X'0/101 "'N(O, 1) for any nonzero

0. If we then apply a polar transformation we have
*( ))
'Trp/2 . OOI p--1
E0 vol ( C X = f(p/ 2+1)
4>(a-r)dr
r
0

=
Note that 'TrP/ 2 / f(p/2

+ 1) is the

(2.13)

'Trp/2
ai (a-t)P e-t2/2
f(p/2+1) - p - f21r dt .
-oo

volume of a p-sphere of radius 1, so the pth root of the integral

in (2.13) is, effectively, the radius of the set. For p = 1 we can write

but for other values of p the integral is harder to evaluate. Table 1 gives some values of the pth root
of Eo vol(C*(x)) and, for comparison, the corresponding values for C0 (x), the usual confidence
sphere.
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Table 1
Effective volume (pth root of expected volume) of C*(x) and C 0(x),
the usual confidence sphere

1
1
1
3
3
3
10
10
10

1-a

[E0 vol C*(X)] 1/P

[E0 vol (C0 (X))] 1/P

Ratio

.90
.95
.99
.90
.95
.99
.90
.95
.99

2.66
3.33
4.66
2.03
2.36
3.01
2.35
2.58
3.04

3.29
3.92
5.15
4.03
4.50
5.45
4.39
4.69
5.29

0.809
0.849
0.905
0.504
0.524
0.552
0.535
0.550
0.575

Of course, for 0 ::/= 0, Eo vol(C*(x)) will grow larger than Eo vol(C 0(x)) (which is constant in

0), the discrepancy increasing as I0 I increases.

We illustrate this with Figure 3, which compares

realized values of the two sets for a variety of x values. Note that the different graphs have different
scales, and the value of x is the center of the sphere.
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3. The Bayes/Frequentist Interpretation
Interestingly, the same mathematical technique that produces the 1- a confidence set of
minimum expected volume at a particular (} also minimizes the expected Bayesian volume using a
prior for 0. If X"" f( · I0) where (} has a prior distribution

1r,

then the expected Bayesian volume of a

set C(x) is
(3.1)

We now seek to minimize (3.1), a Bayesian measure, among all sets C(x) that satisfy the frequentist
coverage probability constraint, P 0

(o E C(x)) ~ 1-a.

In Section 2, the minimizing set was constructed from testing H0
equivalently, H0

:

: (}

= 00

vs HI : ()

= 0 or,

X "" f(x I00 ) vs. HI: X "" f(x I0). In the Bayesian formulation, the minimizing set is

constructed from the test
H0

where m11"(x)

:

= Je f(x I0) 11"(0) dO.

X "" f(x I00 )

vs H1 : X "" m11"(x) ,

The confidence set is, therefore, given by

C~(x) ={(} : f(x I0) ~ m?r(x)
where k(O) is chosen so that P0
Theorem 3.1:

(o E C~(x)) = 1- a.

I k(O)} ,

(3.2)

We have the following theorem

Let X"" f(x I0), (}"" r(O), and C~(x) be given by (3.2).

The confidence set C~(x)

minimizes the expected Bayesian volume (3.1) among alll-a confidence sets.
Proof:

For any confidence set C(x) we have
E,..vol(C(X)) =.

J[J

e

vol(C(x))f(xiO)dx] 1r(O)dO =

$

J

vol(C(x)) m?r(x)dx.

$

.

Now proceed as in the proof of Theorem 2.1, with m,..(x) in place of f(x I0).

0

For illustration, consider again the normal case X"" N(O, I) and ()"" N(O,r 2I). The marginal
distribution of X is N(o, (r2 +1)I), and the confidence set is

C~(x) ={0 'In- r;: 1 xi'~ k*(O)}
where (r 2+1

I r f k*(O) is the upper
2

noncentrality parameter

I(} 12 jr2.

(3.3)

a critical point of a noncentral chi-squared distribution with

It can be shown that as r 2 -+ 0 this set reduces to C*(x) of the

previous section and, as r 2 -+ oo, this set approaches the usual sphere

c0(x).
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4. Generalizations to the Case of Unknown Variance
The set C*(x) of (2.8) is optimal in cases where there are no nuisance parameters, and the
normal examples of Section 2.2 all reflect this. Of course, the more practical problems usually involve
nuisance parameters, and we now consider that case.

We restrict our discussion to the normal

distribution with unknown mean and variance.
With a sample

x 1, · ··,

Xn from n(O, u2) with both parameters unknown, there are two ways of

generalizing the procedure of Section 2. The first, which is perhaps the more obvious way, is to test
the hypotheses
(4.1)

Using a standard Student's t test, this leads to intervals of the form
Ct(x, s)

= {0 :min( 0, x- ta, n- 1 }n) ~ 0 ~max( 0, x + ta, n- 1 }n )} ,

(4.2)

where t a n- 1 is the upper a cutoff from Student's t distribution with n- 1 degrees of freedom. It is

'

straightforward to verify that Ct(x, s) is a 1-a confidence interval, although it doesn't enjoy the
same optimality properties as the interval (2.8). This interval was also considered by Hsu, Hwang,
Liu, and Ruberg (1993), although they did not investigate its optimality.

We detail its exact

optimality below.
For this problem it is natural to consider only confidence 6ets related to the usual (scaleinvariant) t-tests of H0 • This means that the inclusion probabilities of the confidence set must be of
the form
(4.3)

Note that the intervals of (4.2) have this form.
A second, perhaps less obvious way of generalizing Section 2.2 is to modify the hypotheses of
(2;6) by dividing by u to obtain

u0 : ~ = 'lo
where

'7o is a fixed constant. On defining

parameter problem.

'1

vs.

u1 : ~ = o ,

(4.4)

= Oju, we see that we are reduced to considering a one-

In practical terms, the hypotheses (4.4) are also quite interesting, because the

"signal-to-noise ratio" '1

= Oju

is often of interest.

We will see that (4.4) leads to a confidence

interval for TJ that is different from any confidence sets for 0, in particular (4.2).
For the hypotheses (4.4) a reasonable invariant procedure will be of the form
(4.5)

with corresponding confidence intervals given by

ct(x,

s)

= {TJ:f(x/sl TJ) ~f(x/sl O)jk(77)},

I

(4.6)

where f(x/s TJ) is the noncentral t distribution with noncentrality parameter 1J and n -1 degrees of
freedom.

The function k( 1J) is chosen so that

ct is a

1- a confidence set, c;hat is, so that the
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corresponding tests in (4.4) have level a.
normal (u known) intervals.

Figure 4 shows a plot of these intervals, along with the

It is interesting to note that the resulting boundaries are curved, in

contrast to the straight line boundaries in the known u case.
Construction of the intervals given by (4.6) is actually quite straightforward, exploiting
monotonicity properties of both the density and distribution function of the noncentral t. Note first
that since f( t Iq) has monotone likelihood ratio, the acceptance region of the test (4.4), that is H0 : '7
vs. H1 : '7

= 0, is given by

Now the distribution function, F(t Iq), is decreasing in q, so an a-level test is constructed by solving
F(tl k}1 (t)) =a:
and setting '7u(t)

F(tl k21 (t)) = 1-a:,

and

= k}1(t) and '7L(t) = k21(t) yields
Cifx/s)

= { q:min(o, fJL("x/s))~ '1 ~ max(o, fJu(x/s))}.

Note that tdis construction holds, in general, as long as the density satisfies suitable
monotonicity conditions. It aiso follows that the confidence interval ( '7 £< t ), '1u( t)) is a 1- 2a: interval.
For both the set-ups leading to (4.1) and {4.4) we can establish optimality properties of the
resulting confidence sets.
Theorem 4.1:

Among all 1-a: confidence sets for ()of the form (4.3), the intervals (4.2) minimize

Eo,u ( vol ( C( X, S))) for every u 2 > 0.
Proof:

As in the proof of Theorem 2.1, use the Ghosh-Pratt identity to write
00

Eo,u ( vol(C(X, S))) =

J

Po,u(9eC(X, S))d9.

-oo

Among all 1-a: confidence sets of the form (4.4) the integrand is minimized for each() by the Ct of
(4.2), because these intervals correspond to most powerful level a invariant tests of the hypotheses
D

(4.1).
Theorem 4.2:

Among all invariant 1-a: confidence sets for fJ

Eo,u ( vol(C(X,
Proof:

= () / u,

the intervals (4.6) minimize

s>)).

This follows from Theorem 2.1 upon taking into account the monotone likelihood ratio

property of the noncentral t distribution.

D

Without the restriction (4.3) the confidence intervals (4.2) are not optimal. In fact, they are not
even admissible, since it is possible to construct 1-a confidence intervals with smaller expected length
for every () = 0, u > 0. This is possible because the results of Brown and Sackrowitz (1984) enables
construction of level a: tests, fPBs(9IX, S) of (4.1), whose power strictly dominates that of the one-
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sided t-tests leading to (4.2) Consequently, this family of critical functions leads to intervals which
dominate those of (4.2), as can be seen by applying the Ghosh-Pratt identity as in the proof of
Theorem 4.1.
For each 6,
since

the

tT

the (1-a) confidence intervals constructed above have coverage exceeding 1-a,

tests

inf {P6,u(thCBs(X,

of

Brown

and

5))16, u} = 1-a.

Sackrowitz

have

size

smaller

than

a.

But

We do not know whether the intervals CBs are admissible.

Brown and Sackrowitz show their tests are admissible for testing

Ho: 6 = 60 , tT > 0 vs. either HI : 6 > 0

if 60 < 0 or HI :6 < 0 if 60 > 0; however, they do not prove admissibility for H0 , HI of (4.1) as would be
needed to establish admissibility of CBS·
By contrast, the intervals in Theorem 4.2 are admissible for pfu. This is because the tests
involved are UMP invariant and hence are Bayes among invariant tests. The invariance group here is
the group of scale tramsformations and, applying the results of Brown and Fox (1974), a procedure
that is Bayes among invariant procedures is admissible.

Admissibility of the tests implies

admissibility of the confidence sets.
Generalizations to higher dimensions should also be of interest. Presumably, the

lim~on

does

not appear here because the relevant distributions are multivariate t rather than multivariate normal
as in Section 3.

-135. ConnectioDS with Bioequivalence
The intervals discussed here, particularly the form (4.2), have seen practical use in
bioequivalence testing. This brings us to the interesting connection between bioequivalence and the
lim~n

of Pascal.

The problem of declaring bioequivalence is typically that of deciding whether the difference of
two population means, I'C p 2 , is close to zero. Typically, l't and p 2 represent mean responses of two
different types of treatments or drugs (treatments vs. control, oral vs. injection, brand name vs.
generic) and the interest (usually of pharmaceutical companies) is to demonstrate that the effects are
equivalent, yielding bioequivalent formulations of the treatment.

At present, a typical statistical

approach is to test
(5.1)
where 6 is a specified threshold. Rejection of such a test leads to the declaration of bioequivalence.
Note that what is typically the "null hypothesis" is placed in the alternative, as this is the research
hypothesis of interest. One of the first researchers to formulate the bioequivalence problem in this
was Anderson and Hauck (1983). (See also Hauck and Anderson 1984, 1992. The

lat~er

is a review

paper.)
A technique of carrying out a test of (5.1), as required by the FDA {FDA, 1992), is to perform
two one-sided tests, as described by Schuirmann {1987), for example.

This procedure establishes

bioequivalence of l't and p 2, at level a, if both of the following two one-sided test of (J = p1 -1'2 reject
the null hypothesis at level a:

i) H0 : 9 ~ -6

vs.

H1 : 9 > -6

ii) H0 : 9 ~ 6

vs.

H1 : 9 < 6

(5.2)

It ·is interesting to note that (5.2) is a case of an intersection-union test, as developed by Berger

{1982).

As the overall hypothesis of interest, that -6 ~ (J

~

6 is an intersection of the two other

hypotheses, individual a-level tests lead to an overall a-level test for (5.1). Additionally, referring
to the discussion following (4.6), it turDS out that Schuirmann's procedure leads to basing the
conclusion on the non-truncated confidence interval, which seems to have confidence 1-2cr, the wrong
level. The a-level is actually correct, however, the intervals are wider than necessary.
Although interest has usually centered around the testing problem in (5.1), there is also
considerable interest (and benefit) in constructing confidence intervals for p 2 -p1 •

Given a 1- a

confidence interval C(x) for p 2 -p1 , an a-level test of (5.1) can be conducted by rejecting H0 whenever
C{x) C (-6, 6), as proposed by Westlake (1972, 1976). (Notice that this use of confidence sets as tests
is reversed from the usual use.

The values of p 2 -p 1 in the interval (-6, 6) are those for which

bioequivalence will be declared, which is the alternative hypothesis.)

-14-

The confidence set approach to bioequivalence testing has an added benefit in that the constant
6 does not have to be prespecified. Indeed, for a given 1-a bioequivalence confidence set C(x), and
any set ~. we could conclude H1 : p.1 - p.2 £a if C(x) C ~. It then follows that C(x) is the smallest set
of parameter values p.1 - p. 2 for which the data will reject H0 (and hence conclude bioequivalence).
Recent research has continued to take the confidence interval approach to bioequivalence. The
work of Westlake (1976) was apparently prompted by the mismatch in error probabilities of
Schuirmann's procedure (a for the test and 2a for the interval). Although Westlake's 1-a interval
does not correspond to Schuhmann's a-level test, it led to the further research of Bofinger (1985) and
Hsu et a/. (1993), who proposed the interval (4.2).

This 1-a interval, which is shorter than

Westlake's (1976) interval, corresponds to the level a two-one-sided tests procedure. Generalizations
of this problem, including a nonparametric approach, are discussed in Hsu et a/. (1993).
There are other formulations of the bioequivalence hypothesis, formulations that lead to
alternate tests and confidence intervals.

For example, one could specify 6 of (5.1) in terms of the

variance 0'; that is, two procedures are declared bioequivalent if their mean difference is no more than
a specified proportion of their variance. Of course, this formulation leads directly to the hypotheses
specified in (4.4), and to the noncentral t-based intervals of (4.6). Although this formulation of the
bioequivalence problem has been used, the optimal procedure of (4.6) has not been employed.
Lastly, the bioequivalence problem can be a multivariate one, where the full advantage of the
lim~on

can be enjoyed.

To test the bioequivalence of p formulations, one might specify a set

(possibly a hyperrectangle) in which the differences must lie. By constructing a
set, overall bioequivalence can be examined.
confidence set falls entirely within

lim~on

a

confidence

Bioequivalence would be concluded if the

lim~on

a.

We illustrate this last situation with data from Ruberg and Stegeman (1991), on equivalence of
batch degradation slopes. (We make a simplifying (but seemingly reasonable) assumption about the
batch variation. For an alternative analysis, based on multiple comprison techniques, see Ruberg and
Hsu (1992).)

Each of p = 6 batch slopes, {31 , • · ·, {36 , is used to estimate the shelf-life of a product.

Here we look at the bioequivalence of the differences
i =2,···,p.

The data are assumed to be independent normal with known variance; that is, we observe

(3i ""n(p,
case, :E

0' 2 ).

This results in observed Oi = (3i- (3 1 that are correlated,

= 0' 2(1 + J), J

being a vector of ones. In general, for

0"" N(O,

0- N(O,

:E) where, in this

:E), the 1-a lim~on confidence

set is
(5.2)

where za is the upper a cutoff point from a univariate standard normal distribution. This set reduces

-151

1

to the form of (2.10) with the transformation '1 = r;2(J, i) = r;29. The set (5.2) is somewhat of an
elliptical

lim~on,

and is shown in Figure 5.

dimensional set, which gives the smallest

We show two-dimensional projections of the five-

a for which bioequivalence will be declared.

Acknowledgment: We thank Jason Hsu for many interesting discussions about different aspects of

this problem, and W eizhen Wang for numerical calculations leading the Figure 4.
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Figure 1. The lim~on of Pascal r=h+acos,B.

If h<a the lima~on has an inner

loop, which does not occur in the confidence set.
{B:IBI~Za+IX!cos,B}

The confidence set

is, in effect, a "positive-part" lim~on.

>a

b
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-0.5
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Figure 2. Comparison of C*(x) (solid lines) of (2.10) with the usual 90% confidence
interval (dashed lines).
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lim~on

Figure 3. Two-dimensional

(solid lines) and usual confidence sphere (dashed

lines) for four different data points. The confidence sphere has a constant
radius, while the

lima~on

enlarges as the data move away from the origin.

x=(2,.5)

x=(O,O)

~r-----------~----------~-----------,

,.---

........

/

..-

......

........

.....

'\

/

I

......

"\

\

I

\

\

I

I

I
\

0

----

/

\
I

0

/

' .....

~

\

•

I

\

'

I

I

I

/

I

/

I
/

N

~

I

-4

-2

I

2

0

-1

x=(4,2)

3

5

x=(10,7)
~r-----------~----------~-----------,

ID

•

I
l

\

I

\

~

I

7~----~------~------~----~------~7
-3

-1

3

5

~

IL_-3----------~----------~9~--------~15

-21-

Figure 4. Comparison of Ci of (4.6) with the normal (known u) interval. The dotted
lines are the normal interval, and the noncentral t interval is shown for a 2
df (solid lines), 5 df (short dashed lines), and 20 df (long dashed lines).
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Figure 5. Two-dimensional projections of the five-dimensional "elliptical lima<;on"
and usual confidence ellipse for the batch degradation data. Note that both

01 and 02 were close to zero,

but

04

was farther from zero, which is reflected

in the size and placement of the respective lima<;ons.
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